Abstract:Jiping Zhang, &ast Xianan Sang, &ast Yichao Yuan, Jiawei Shen, Yuanyuan Fang, Minjing Qin, Hangsheng Zheng, Zhihong Zhu College of Pharmaceutical Science, Zhejiang Chinese Medical University, Hangzhou, 311402, People's Republic of China &astThese authors contributed equally to this work Correspondence: Hangsheng Zheng; Zhihong Zhu, College of Pharmaceutical Science, Zhejiang Chinese Medical University, Hangzhou, People's Republic of China, Email ; Background: Anthraquinone drugs are widely used in the treatment of tumors. However, multidrug resistance and severe cardiac toxicity limit its use, which have led to the discovery of new analogues. In this paper, 4-Deoxy- &epsiv -pyrromycinone (4-Deo), belonging to anthraquinone compounds, was first been studied with the anti-tumor effects and the safety in vitro and in vivo as a new anti-tumor drug or lead compound. Methods: The quantitative analysis of 4-Deo was established by UV methodology. The anti-cancer effect of 4-Deo in vitro was evaluated by cytotoxicity experiments of H22, HepG2 and Caco2, and the anti-cancer mechanism was explored by cell apoptosis and cycle. The tumor-bearing mouse model was established by subcutaneous inoculation of H22 cells to evaluate the anti-tumor effect of 4-Deo in vivo. The safety of 4-Deo was verified by the in vitro safety experiments of healthy cells and the in vivo safety experiments of H22 tumor-bearing mice. Tumor tissue sections were labeled with CRT, HMGB1, IL-6 and CD115 to explore the preliminary anti-cancer mechanism by immunohistochemistry. Results: In vitro experiments demonstrated that 4-Deo could inhibit the growth of H22 by inducing cell necrosis and blocking cells in S phase, and 4-Deo has less damage to healthy cells. In vivo experiments showed that 4-Deo increased the positive area of CRT and HMGB1, which may inhibit tumor growth by triggering immunogenic cell death (ICD). In addition, 4-Deo reduced the positive area of CSF1R, and the anti-tumor effect may be achieved by blocking the transformation of tumor-associated macrophages (TAMs) to M2 phenotype. Conclusion: In summary, this paper demonstrated the promise of 4-Deo for cancer treatment in vitro and in vivo. This paper lays the foundation for the study of 4-Deo, which is beneficial for the further development anti-tumor drugs based on the lead compound of 4-Deo. Keywords: 4-deoxy- &epsiv -pyrromycinone, lead compound, drug safety, drug efficacy, anti-tumor drug Graphical According to the International Agency for Research on Cancer, there were close to 20 million new cases of cancer alongside 9.7 million cancer deaths in 2022. 1 These data show that the threat of cancer to human life and health is increasing, so the search for new drugs or new therapeutic targets is essential for the treatment of cancer. Even though macromolecular drugs have been attracting more and more attention, especially since the occurrence of novel coronavirus pneumonia, 2,3 the development of small molecular drugs is still one of the focuses of new drug development. Compared with macromolecular drugs, small molecule drugs can avoid the local or systemic adverse reactions caused by excipients and the sensitivity of proteins to pH, have higher stability, and in particular, reduce the cost of drug development. 4 What's more, small molecule drugs can be obtained in more diverse ways. When our team subjected Streptomyces sp. BG-11 to large-scale fermentation, which was isolated from rhizosphere soils of the plant Atractylodes macrocephala Koidz from Zhejiang Province, China, we found that the fermentation products had antitumor ability. After several isolation screens and comparison with the literature, we found it is the 4-Deoxy- ε -pyrromycinone (4-Deo). 5,6 4-Deo belongs to anthraquinone compounds. As we all know, anthraquinone drugs, including daunorubicin, doxorubicin, epirubicin, pirarubicin, aclamycin, etc. are widely used in the treatment of hematological malignancies and solid tumors. 7–9 However, regardless of its therapeutic effects, multidrug resistance and severe cardiac toxicity are important limitations of anthracycline drug therapy, which have led to the discovery of new analogues. 10–12 The structure of 4-Deo is similar to that of commonly used clinical compounds, both of which have a four membered ring mother nucleus. However, 4-Deo has an additional carboxyl group in its structure, making it a lead compound for anti-tumor drugs. More importantly, through literature review, we found that current research only determined the structure of the compound 5 and only Aiai's paper has proved its anticancer activit -Abstract Truncated-

New CDDO Arylboronate Ester Derivatives with High Selectivity and Low Toxicity

Design and synthesis of novel mitochondria-targeted CDDO derivatives as potential anti-cancer agents

Synthesis and Anticancer Activity of CDDO and CDDO-Me, Two Derivatives of Natural Triterpenoids

Synthesis and in Vitro Anticancer Activity of 6,7-Methylenedioxy (or 5-Hydroxy-6-methoxy)-2-(substituted Selenophenyl)Quinolin-4-One Analogs

Synthesis And Biological Evaluation Of 3-Aryl-Quinoxaline-2-Carbonitrile 1,4-Di-N-Oxide Derivatives As Hypoxic Selective Anti-Tumor Agents

Synthesis and Biological Evaluation of 3-Aryl-quinoxaline-2-carbonitrile 1,4-Di-<em>N</em>-oxide Derivatives as Hypoxic Selective Anti-tumor Agents

Design, synthesis and antitumor activity of novel 4-oxobutanamide derivatives

Discovery of Novel Heteroarylmethylcarbamodithioates As Potent Anticancer Agents: Synthesis, Structure-Activity Relationship Analysis and Biological Evaluation.

Design, Preparation and Studies Regarding Cytotoxic Properties of Benzyl Oleanates

‘Click Chemistry’ Synthesis of Novel Natural Product-Like Caged Xanthones Bearing a 1,2,3-Triazole Moiety with Improved Druglike Properties As Orally Active Antitumor Agents

Discovery, synthesis, and anti-cancer evaluation of 10-Pterostilbene methylamine hydrochloride derivatives as potential COX-2 and Topo I dual inhibitors

Synthesis of Oleanolic Acid-Dithiocarbamate Conjugates and Evaluation of Their Broad-Spectrum Antitumor Activities

Efficient and regioselective synthesis of ortho-diiodinated homobenzylic alcohol derivatives: in silico evaluation as potential anticancer IDO/TDO inhibitors

Synthesis and Anti-Cancer Activity Studies of Dammarane-Type Triterpenoid Derivatives

Oleanolic acid derivative Dex-OA has potent anti-tumor and anti-metastatic activity on osteosarcoma cells in vitro and in vivo

Synthesis and Cytotoxicities of Dioscin Derivatives with Decorated Chacotriosyl Residues

Discovery of Biaryl Amide Derivatives As Potent, Selective, and Orally Bioavailable RORγt Agonists for Cancer Immunotherapy.

Acylation of Oleanolic Acid Oximes Effectively Improves Cytotoxic Activity in In Vitro Studies

Synthesis and cytotoxicity of novel 14α-O-(andrographolide-3-subsitutedisoxazole-5-carboxylate) derivatives

Synthesis, crystal structure, Hirshfeld surface, computational and biological studies of spiro-oxindole derivatives as MDM2-p53 inhibitors

4-Deoxy-ε-Pyrromycinone: A Promising Drug/Lead Compound to Treat Tumors